Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Ravdin

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
JAMA Oncology|January 10, 2020
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast CancerWendy A Woodward, William E Barlow, Reshma Jagsi, et al.
JAMA|October 21, 2010
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal womenRowan T Chlebowski, Garnet L Anderson, Margery Gass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissuesDavid L Rimm, Torsten O Nielsen, Scott D Jewell, et al.
Lancet (London, England)|December 17, 2009
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialKathy S Albain, William E Barlow, Peter M Ravdin, et al.
Clinical Breast Cancer|April 1, 2019
Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways StudyVictoria Larsen, William E Barlow, Jun J Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2017
Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 yearsEllen G Engelhardt, Alexandra J van den Broek, Sabine C Linn, et al.
The New England Journal of Medicine|June 4, 2019
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast CancerJoseph A Sparano, Robert J Gray, Peter M Ravdin, et al.
The New England Journal of Medicine|June 5, 2018
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerJoseph A Sparano, Robert J Gray, Della F Makower, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
JAMA Oncology|January 10, 2020
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast CancerWendy A Woodward, William E Barlow, Reshma Jagsi, et al.
JAMA|October 21, 2010
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal womenRowan T Chlebowski, Garnet L Anderson, Margery Gass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2011
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissuesDavid L Rimm, Torsten O Nielsen, Scott D Jewell, et al.
Lancet (London, England)|December 17, 2009
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialKathy S Albain, William E Barlow, Peter M Ravdin, et al.
Clinical Breast Cancer|April 1, 2019
Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways StudyVictoria Larsen, William E Barlow, Jun J Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2017
Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 yearsEllen G Engelhardt, Alexandra J van den Broek, Sabine C Linn, et al.
The New England Journal of Medicine|June 4, 2019
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast CancerJoseph A Sparano, Robert J Gray, Peter M Ravdin, et al.
The New England Journal of Medicine|June 5, 2018
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerJoseph A Sparano, Robert J Gray, Della F Makower, et al.
Pageof 4